4//SEC Filing
Danahy Kevin Patrick 4
Accession 0001437749-25-029646
CIK 0001625101other
Filed
Sep 21, 8:00 PM ET
Accepted
Sep 22, 9:24 PM ET
Size
13.8 KB
Accession
0001437749-25-029646
Insider Transaction Report
Form 4
Danahy Kevin Patrick
Chief Commercial Officer
Transactions
- Exercise/Conversion
Common Stock
2025-09-18$1.53/sh+20,000$30,600→ 63,298 total - Sale
Common Stock
2025-09-18$18.49/sh−20,000$369,800→ 43,298 total - Sale
Common Stock
2025-09-19$18.48/sh−400$7,392→ 43,298 total - Exercise/Conversion
Stock Option (right to buy)
2025-09-19−400→ 429,600 totalExercise: $1.53Exp: 2032-09-23→ Common Stock (400 underlying) - Exercise/Conversion
Common Stock
2025-09-19$1.53/sh+400$612→ 43,698 total - Exercise/Conversion
Stock Option (right to buy)
2025-09-18−20,000→ 430,000 totalExercise: $1.53Exp: 2032-09-23→ Common Stock (20,000 underlying)
Footnotes (3)
- [F1]These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 14, 2025.
- [F2]The price in column 4 is the weighted average price per share sold. The price per share actually received by the reporting person ranged from $18.48 to $19.48 per share. For all transactions reported in this Form 4 using a weighted average price, the reporting person undertakes upon request by the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the range.
- [F3]Options granted on September 23, 2022, to acquire up to 450,000 shares of Common Stock, in connection with reporting person's promotion, with 25% vesting on each anniversary of grant, pursuant to the terms of an amendment to reporting person's Employment Agreement dated February 9, 2022.
Documents
Issuer
PULSE BIOSCIENCES, INC.
CIK 0001625101
Entity typeother
Related Parties
1- filerCIK 0001913245
Filing Metadata
- Form type
- 4
- Filed
- Sep 21, 8:00 PM ET
- Accepted
- Sep 22, 9:24 PM ET
- Size
- 13.8 KB